PENTHROXâ„¢ in the Canadian Emergency Department (ED)
common.study.values.description
“PENTHROXâ„¢ in the Canadian Emergency Department (ED)”
This Canadian, multi-centre, prospective, real world study is designed to evaluate the effectiveness of low dose methoxyflurane (MEOF) (PENTHROXa"c) for the treatment of moderate to severe pain associated with trauma in the Canadian ED.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Methoxyflurane 3mL
As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROXâ„¢ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROXâ„¢ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROXâ„¢ inhaler with the Activated Carbon (AC) chamber.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase IV Real World Study on the Use of Low Dose Methoxyflurane (PENTHROXâ„¢) for the Treatment of Moderate to Severe Trauma Pain in the Canadian Emergency Department
common.study.values.clinical-trial-id
NCT03868436
participant.views.study.view.id
bo2mka
